These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29088743)

  • 1.
    Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
    Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Conde E; Hernandez S; Rodriguez Carrillo JL; Martinez R; Alonso M; Curto D; Jimenez B; Caminoa A; Benito A; Garrido P; Clave S; Arriola E; Esteban-Rodriguez I; De Castro J; Sansano I; Felip E; Rojo F; Dómine M; Abdulkader I; Garcia-Gonzalez J; Teixido C; Reguart N; Compañ D; Insa A; Mancheño N; Palanca S; Juan-Vidal O; Baixeras N; Nadal E; Cebollero M; Calles A; Martin P; Salas C; Provencio M; Aranda I; Massuti B; Lopez-Vilaro L; Majem M; Paz-Ares L; Lopez-Rios F
    JTO Clin Res Rep; 2024 Apr; 5(4):100653. PubMed ID: 38525319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalog of 5' fusion partners in
    Ou SI; Zhu VW
    JTO Clin Res Rep; 2020 Jun; 1(2):100037. PubMed ID: 34589933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hidrocystoma-like tumours with RET or ALK fusion: a study of four cases.
    Goto K; Kervarrec T; Tallet A; Macagno N; Pissaloux D; Fouchardière A; Battistella M; Kajiwara M; Nagao T; Fujita I; Kajimoto K; Goto H; Matsumura H; Takai T
    Pathology; 2024 Oct; 56(6):865-873. PubMed ID: 39009490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.
    Choi YJ; Choi M; Park J; Park M; Kim MJ; Lee JS; Oh SJ; Lee YJ; Shim WS; Kim JW; Kim MJ; Kim YC; Kang KW
    Biomed Pharmacother; 2024 Feb; 171():116124. PubMed ID: 38198957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Gadgeel S; Shaw AT; Barlesi F; Crinò L; Yang JC; Dingemans AC; Kim DW; de Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou SI
    Br J Cancer; 2018 Jan; 118(1):38-42. PubMed ID: 29149104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
    Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
    Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    Nakanishi Y; Masuda S; Iida Y; Takahashi N; Hashimoto S
    J Thorac Oncol; 2017 Dec; 12(12):e202-e204. PubMed ID: 29169525
    [No Abstract]   [Full Text] [Related]  

  • 9. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
    Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with
    Zhu Q; Hu H; Jiang F; Guo CY; Yang XW; Liu X; Kuang YK
    Oncotarget; 2017 Sep; 8(43):75372-75380. PubMed ID: 29088872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
    Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
    Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
    Dong ZY; Zhang JT; Liu SY; Su J; Zhang C; Xie Z; Zhou Q; Tu HY; Xu CR; Yan LX; Li YF; Zhong WZ; Wu YL
    Oncoimmunology; 2017; 6(11):e1356145. PubMed ID: 29147605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report.
    Zhu Z; Chai Y
    Medicine (Baltimore); 2017 Nov; 96(45):e8652. PubMed ID: 29137103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
    Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; Cecere FL; Giannarelli D; Luciani A; Bearz A; Tuzi A; Scotti V; Tonini G; Galetta D; Carta A; Soto Parra H; Rebonato A; Morabito A; Chiari R
    Future Oncol; 2018 Feb; 14(4):353-361. PubMed ID: 29135281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
    Drilon A; Hu ZI; Lai GGY; Tan DSW
    Nat Rev Clin Oncol; 2018 Mar; 15(3):151-167. PubMed ID: 29134959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceritinib Enhances the Efficacy of Trametinib in
    Verduzco D; Kuenzi BM; Kinose F; Sondak VK; Eroglu Z; Rix U; Smalley KSM
    Mol Cancer Ther; 2018 Jan; 17(1):73-83. PubMed ID: 29133622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.